MicroRNA-33a regulates cholesterol synthesis and cholesterol efflux-related genes in osteoarthritic chondrocytes by Fotini Kostopoulou et al.
Kostopoulou et al. Arthritis Research & Therapy  (2015) 17:42 
DOI 10.1186/s13075-015-0556-yRESEARCH ARTICLE Open AccessMicroRNA-33a regulates cholesterol synthesis and
cholesterol efflux-related genes in osteoarthritic
chondrocytes
Fotini Kostopoulou1,2, Konstantinos N Malizos2,3, Ioanna Papathanasiou1 and Aspasia Tsezou1,2,4*Abstract
Introduction: Several studies have shown that osteoarthritis (OA) is strongly associated with metabolism-related
disorders, highlighting OA as the fifth component of the metabolic syndrome (MetS). On the basis of our previous
findings on dysregulation of cholesterol homeostasis in OA, we were prompted to investigate whether microRNA-33a
(miR-33a), one of the master regulators of cholesterol and fatty acid metabolism, plays a key role in OA pathogenesis.
Methods: Articular cartilage samples were obtained from 14 patients with primary OA undergoing total knee
replacement surgery. Normal cartilage was obtained from nine individuals undergoing fracture repair surgery.
Bioinformatics analysis was used to identify miR-33a target genes. miR-33a and sterol regulatory element-binding
protein 2 (SREBP-2) expression levels were investigated using real-time PCR, and their expression was also assessed
after treatment with transforming growth factor-β1 (TGF-β1) in cultured chondrocytes. Akt phosphorylation after
treatment with both TGF-β1 and miR-33a inhibitor or TGF-β1 and miR-33a mimic was assessed by Western blot
analysis. Furthermore, we evaluated the effect of miR-33a mimic and miR-33a inhibitor on Smad7, a negative
regulator of TGF-β signaling, on cholesterol efflux-related genes, ATP-binding cassette transporter A1 (ABCA1),
apolipoprotein A1 (ApoA1) and liver X receptors (LXRα and LXRβ), as well as on matrix metalloproteinase-13
(MMP-13), using real-time PCR.
Results: We found that the expression of miR-33a and its host gene SREBP-2 was significantly elevated in OA
chondrocytes compared with normal chondrocytes. Treatment of cultured chondrocytes with TGF-β1 resulted in
increased expression of both miR-33a and SREBP-2, as well as in rapid induction of Akt phosphorylation, whereas
TGF-β-induced Akt phosphorylation was enhanced by miR-33a and suppressed by inhibition of miR-33a, as a
possible consequence of Smad7 regulation by miR-33a. Moreover, treatment of normal chondrocytes with
miR-33a resulted in significantly reduced ABCA1 and ApoA1 mRNA expression levels and significantly elevated
MMP-13 expression levels, promoting the OA phenotype, whereas miR-33a’s suppressive effect was reversed using
its inhibitor.
Conclusions: Our findings suggest, for the first time to our knowledge, that miR-33a regulates cholesterol synthesis
through the TGF-β1/Akt/SREBP-2 pathway, as well as cholesterol efflux-related genes ABCA1 and ApoA1, in OA
chondrocytes, pointing to its identification as a novel target for ameliorating the OA phenotype.* Correspondence: atsezou@med.uth.gr
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Osteoarthritis (OA), the most common form of arthritis,
is a chronic degenerative joint disease that affects millions
of people worldwide [1]. It is thought of as a “joint failure”
due to molecular changes that take place in all joint tissues
[2]. OA is a complex disorder in which increased mechan-
ical load and inflammation, combined with genetic predis-
position, trauma and obesity, contribute to its initiation
and progression [3].
OA is now considered as a disease with a variety of
phenotypes, including the metabolic phenotype, because
OA and the metabolic syndrome (MetS) are tied to-
gether in fundamental ways [4]. Their association is fur-
ther supported by a number of studies linking OA to
hypertension, type 2 diabetes and dyslipidemia, all char-
acteristics of MetS [4,5], whereas common molecules
seem to be involved in the pathophysiology of both OA
and metabolic disturbances, highlighting OA as a new
facet of MetS [6].
Imbalances of lipid traffic or metabolic homeostasis may
either contribute to or represent the primary disruption
associated with the development of many lipid-related dis-
eases [7]. In that regard, our group has previously investi-
gated the metabolic aspect of OA by studying the
involvement of adipokines and lipid-related genes in its
pathogenesis. Osteoarthritic chondrocytes were found to
internalize lipids and exhibit reduced expression of genes
regulating reverse cholesterol transport, such as ATP-
binding cassette transporter A1 (ABCA1), apolipoprotein
A1 (ApoA1), or their transcriptional regulators liver X re-
ceptors (LXRα and LXRβ), resulting in advanced cell tox-
icity due to accumulation of cholesterol [8-10].
Under normal conditions, biosynthesis of cholesterol is
directly regulated by the cholesterol levels present. In OA,
we have recently shown that sterol regulatory element-
binding protein 2 (SREBP-2), a transcription factor that
activates genes of cholesterol metabolism and biosyn-
thesis, such as 3-hydroxy-3-methylglutaryl-coenzyme
A reductase, was significantly elevated. We also pro-
vided evidence for its induction by transforming
growth factor-β1 (TGF-β1) through the phosphoinosi-
tide 3-kinase (PI3K)/Akt pathway, a molecular mech-
anism responsible for the increase in cholesterol
synthesis observed in OA [11].
All of the above information suggests that both pro-
cesses—cholesterol synthesis and cholesterol efflux—are
deregulated and contribute to OA pathogenesis. How-
ever, so far, the underlying mechanisms for their inter-
action remain unknown.
In an attempt to open novel avenues in therapeutic strat-
egies for OA, a lot of studies have focused on microRNAs
(miRNAs), a rapidly evolving research field. miRNAs are
small (20 to 24 nucleotides long), noncoding RNAs that
control gene expression at the posttranscriptional level.The mature miRNAs bind to specific, fully or partially com-
plementary sequences in the 3′ untranslated regions (3′-
UTRs) of mRNA targets and promote their degradation or
prohibit their translation into functional proteins [12-14].
In rare cases, the interaction of miRNAs with a target
mRNA takes place at the 5′-UTR or at protein-coding re-
gions [14]. Most miRNA target sites have perfect pairing to
the region near the miRNA 5′ end (seed region) or to the
region near the miRNA 3′ end (3′ compensatory pairing).
Interestingly, “centered pairing,” a unique class of miRNA
target sites, has been identified, in which the interaction be-
tween miRNA and mRNA takes place in the central region
of the miRNA [15].
Recent studies have identified the expression profiles
of miRNAs that regulate matrix genes or signaling path-
ways pertinent to OA [16-20], with specific miRNAs re-
lated to both cartilage and adipose tissue biology [20,21].
miRNA-33a (miR-33a) is highly conserved in many ani-
mal species and is one of the master regulators of chol-
esterol and fatty acid metabolism [22], and it is located
within intron 16 of the human SREBP2 gene. It regulates
the expression of genes involved in cholesterol export
and high-density lipoprotein (HDL) biogenesis (ABCA1,
ABCG1 and NPC1) [23-25], fatty acid oxidation (CPT1A,
CROT, HADHB and AMPKa), bile secretion (ABCB11
and ATP8B1) and insulin signaling (IRS2 and SIRT6)
[26-28]. More specifically, miR-33a has been demonstrated
to have an essential effect on regulating cholesterol metab-
olism in cooperation with its host gene, SREBP2, by
strongly repressing the levels of ABCA1 and thus dampen-
ing cellular cholesterol efflux to ApoA1 in human and mur-
ine macrophages and hepatic cells. Contrarily, inhibition of
endogenous miR-33a increases plasma HDL levels through
positive regulation of ABCA1 expression [23,25,29-31],
serving as useful tool for treating dyslipidemia, cardiovascu-
lar disorders and related metabolic diseases.
However, the role of miR-33a in regulating cholesterol
homeostasis in OA has not been investigated yet. In this
study, we demonstrate that miR-33a expression levels are
significantly increased in OA chondrocytes compared with
normal chondrocytes, being induced by TGF-β1, and that
this miRNA regulates cholesterol synthesis and cholesterol
efflux-related genes in OA chondrocytes.
Methods
Bioinformatics approaches
The online miRNA databases TargetScan 6.2 [32], mi-
Randa [33] and miRDB [34] were used to search miR-33a
target genes.
Osteoarthritic and normal articular cartilage samples
Cartilage tissues were aseptically obtained from patients
with primary OA undergoing total knee replacement
surgery at the Department of Orthopaedics of University
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in this study (11 women and 3 men; mean age: 69.9 ± 7.3
years). Radiographs were obtained before surgery and
graded using the Kellgren-Lawrence system according to
the following criteria: grade 1 (doubtful narrowing of
joint space and possible osteophytes), grade 2 (definite
osteophytes and possible narrowing of joint space),
grade 3 (moderate multiple osteophytes, definite narrow-
ing of joint space and some sclerosis and possible de-
formity of bone ends) and grade 4 (large osteophytes,
marked narrowing of joint space, severe sclerosis and
definite deformity of bone ends). All patients had a
Kellgren-Lawrence grade ≥2. The assessment of the ra-
diographs by two independent expert observers was
blinded. Patients with rheumatoid arthritis and other
autoimmune diseases, as well as chondrodysplasias,
infection-induced OA and posttraumatic OA, were not
included in the study. Normal articular cartilage was ob-
tained from nine individuals (five women and four men;
mean age: 66 ± 4.4 years) undergoing fracture repair sur-
gery who had no history of joint disease and did not
show clinical manifestations compatible with OA when
this was specifically explored by radiographs. Both pa-
tients’ and healthy individuals’ cartilage samples were ob-
tained upon their providing written informed consent.
The method of obtaining consent was approved by the
Institutional Review Board of the University Hospital of
Larissa. The study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the local ethics commit-
tee of the University Hospital of Larissa.
Primary cultures of normal and osteoarthritic articular
chondrocytes
Cartilage samples were cut into small pieces with a scal-
pel and digested at 37°C with 1 mg/ml pronase (Roche
Applied Science, Mannheim, Germany) for 30 minutes,
and then each sample was centrifuged and the pellet
was incubated with 1 mg/ml collagenase P (Roche Ap-
plied Science) for 3 hours at 37°C. Chondrocytes were
counted and checked for viability by trypan blue stain-
ing. More than 95% of the cells were viable after isola-
tion. The isolated chondrocytes were seeded in 25-cm2
culture flasks and incubated with Dulbecco’s modified
Eagle’s medium/Ham’s F-12 (DMEM/F-12) (GIBCO;
Life Technologies, Paisley, UK) plus 5% fetal bovine
serum (GIBCO; Life Technologies) and 100 U/ml
penicillin-streptomycin (HyClone Laboratories, Logan,
UT, USA) at 37°C in an atmosphere of 5% CO2 until
reaching confluence.
RNA extraction
Total cellular RNA containing miRNA was extracted from
cultured chondrocytes using TRIzol reagent (Invitrogen/Life Technologies). RNA was further purified using an
RNeasy Mini Kit (Qiagen, Hilden, Germany). Preservation
of 28S and 18S rRNA species was used to assess RNA in-
tegrity. All the samples included in the study had promin-
ent 28S and 18S rRNA components. The yield was
quantified spectrophotometrically.
Reverse transcription
For RT-PCR experiments, 1 μg of RNA from each sample
was used. Reverse transcription was conducted using the
SuperScript III Reverse Transcriptase kit (Invitrogen/Life
Technologies) according to the protocol provided by the
manufacturer. Osteoarthritic and normal chondrocyte
samples were reverse-transcribed using random primers
(Invitrogen/Life Technologies), miR-33a stem-loop RT
primer (5 pmol in 20-μl reaction volume) or U6 small nu-
clear RNA (RNU6B) stem-loop RT primer (5 pmol in 20-
μl reaction volume) to generate the cDNA according to
the method described by Chen et al. [35]. Stem-loop
primers carried a 3′ overhang of six or seven nucleotides
complementary to the 3′ portion of the respective mature
miRNA sequence.
Quantitative RT-PCR
Expression of ABCA1, ApoA1, LXRα, LXRβ, SREBP-2,
matrix metalloproteinase (MMP)-13, Smad7, glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), mature
miR-33a and RNU6B was determined by real-time PCR
(ABI 7300; Applied Biosystems, Foster City, CA, USA).
Reactions were done in triplicate using 2 μl of cDNA
per reaction. The reactions for miRNA or mRNA were
performed in a 10-μl final volume containing 2 μl of
cDNA (conducted with stem-loop primer (dilution
1:100) or with random primers (dilution 1:5)), 5 μl of
Power SYBR Green PCR Master Mix (Applied Biosys-
tems), 0,3 μl of each primer (forward and reverse) and
2.4 μl of nuclease-free water. All primers used are shown
in Table 1. To quantify the relative expression of each
miRNA or gene, threshold cycle (Ct) values were nor-
malized against the endogenous reference (ΔCt =Ct
(miR-33a) −Ct (U6)) or ΔCt =Ct (target) − Ct (GAPDH))
and were compared with a calibrator using the 2−ΔΔCt
method (2−ΔΔCt =ΔCt (sample) − ΔCt (calibrator)).
Protein extraction and Western blot analysis
Chondrocytes were lysed using lysis buffer containing 30
mM Tris (pH 7.5), 150 mM NaCl, 10% glycerol, 1%
Nonidet P-40 and a cocktail of protease and phosphatase
inhibitors (Roche Applied Science). Protein concentra-
tion was quantified using the Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA, USA) with bovine
serum albumin as standard. Cell lysates from chondro-
cytes were electrophoresed and separated on 10% acryl-
amide gels and transferred to polyvinylidene fluoride
Table 1 Oligonucleotide primers used in cDNA synthesis for the detection of miR-33a and U6 (stem-loop primers) and















aABCA1, ATP-binding cassette transporter A1; ApoA1, Apolipoprotein A1; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; LXR, Liver X receptor; miR-33a,
MicroRNA-33a mature; MMP-13, Matrix metalloproteinase-13; SREBP2, Sterol regulatory element-binding protein 2.
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were probed with anti-total Akt (Santa Cruz Biotech-
nology Europe, Heidelberg, Germany) and anti-p-Akt
(Abcam, Cambridge, UK). Signals were detected using
suitable immunoglobulin G conjugated with horserad-
ish peroxidase. Western blot bands were quantified
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
Treatment with TGF-β1
Primary cultured human chondrocytes were seeded onto
six-well plates at a density of 3 × 105 cells/well. Three
days postseeding, normal chondrocytes were serum-
starved overnight and then cultured in serum-free
DMEM/F-12 in the presence or absence of 10 ng/ml
TGF-β1 (Sigma-Aldrich, St Louis, MO, USA) for 0.5
hours, 2 hours, 6 hours, 24 hours and 48 hours. Each ex-
periment was conducted in triplicate, and the results
from three wells were averaged and considered as n = 1.
RNA was extracted, and real-time PCR analysis was per-
formed (6 hours, 24 hours, 48 hours). Total and
phospho-proteins were extracted, and Western blot ana-
lysis was performed (0.5 hours, 2 hours, 24 hours).
TGF-β1 treatment in normal chondrocytes with
subsequent use of miR-33a inhibitor
Cells were seeded onto six-well plates at a density of 3 ×
105cells/well. Three days postseeding, normal chondro-
cytes were serum-starved overnight and then cultured in
serum-free DMEM/F-12 in the presence or absence of
10 ng/ml TGF-β1 (Sigma-Aldrich) for 6 hours. After 6-
hour culture of normal chondrocytes with TGF-β1, theculture medium was changed and treated with 50 nM
anti-miR-33a or negative control for 24 hours. Each ex-
periment was conducted in duplicate, and the results from
two wells were averaged and considered as n = 1. RNA
was extracted, and real-time PCR analysis was performed.
Transient transfection of microRNA mimic and inhibitor
miRNA mimic (miR-33a), antagomir (anti-miR-33a) or
negative control oligonucleotides were obtained from
Ambion/Life Technologies. Primary cultured normal hu-
man chondrocytes were transfected with 30 nM miR-33a
mimic using Lipofectamine 2000 reagent (Invitrogen/Life
Technologies) for 6 hours, 24 hours and 48 hours. miR-33a
inhibitor (50 nM) was transfected into human osteoarthritic
chondrocytes for 24 and 48 hours. Each experiment was
conducted in triplicate, and the results from three wells
were averaged and considered as n = 1. RNA was extracted,
and real-time PCR was performed as previously described.
Transient transfection of microRNA inhibitor with
subsequent TGF-β1 treatment and transient transfection
of miR-33a mimic plus TGF-β1 in human chondrocytes
Cells were seeded onto six-well plates at a density of 3 ×
105cells/well. Three days postseeding, OA chondrocytes
were serum-starved overnight and then cultured in
serum-free DMEM/F-12 in the presence or absence of
50 nM anti-miR-33a for 24 hours. The culture medium
was changed and treated with 10 ng/ml TGF-β1 (Sigma-
Aldrich) for 2 hours. Normal chondrocytes were serum-
starved overnight and then cultured in serum-free
DMEM/F-12 in the presence or absence of 30 nM miR-
33a and 10 ng/ml TGF-β1 (Sigma-Aldrich) or 10 ng/ml
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ducted in duplicate, and the results from two wells
were averaged and considered as n = 1. Total and
phospho-proteins were extracted, and Western blot
analysis was performed.
Statistical analysis
All statistical analysis was performed using SPSS Statistics
20 software (IBM, Armonk, NY, USA). Gene expression
data were analyzed using Student’s t-test and a confidence
level of 95%. Numerical data were expressed as mean ±
standard error mean (SEM). P < 0.05 was considered sta-
tistically significant.Results
miR-33a expression is elevated in OA chondrocytes
There is evidence that intronic miRNAs are coordinately
expressed and processed with the precursor mRNA in
which they reside [36]. Taking into consideration the fact
that miR-33a is located within intron 16 of the human
SREBP2 gene and that SREBP2 expression is upregulated
in OA [11], we wanted to test whether miR-33a and its
host gene SREBP2 are coexpressed in human chondro-
cytes. We evaluated their expression levels by quantita-
tive RT-PCR and found that they were both significantly
elevated in OA chondrocytes compared with normal
chondrocytes (P < 0.05) (Figure 1A,B).TGF-β1 induces miR-33a expression in human chondrocytes
We have recently shown that SREBP-2 is activated by
TGF-β1 in human chondrocytes through the integrin
alpha-V/PI3K/Akt pathway [11]. We next proceeded to
investigate whether miR-33a expression is also induced
by this growth factor. Normal chondrocytes were treated
with 10 ng/ml TGF-β1 for 6 hours, 24 hours and 48
hours, and we found that both miR-33a and SREBP-2
expression levels were significantly upregulated in chon-
drocytes treated with TGF-β1 compared with untreated
cells (P < 0.05) (Figure 1C–F).Regulation of SREBP-2 expression by anti-miR-33a in
TGF-β1-induced chondrocytes
Because TGF-β1 was found to upregulate SREBP-2 and
miR-33a, normal chondrocytes were treated with 10
ng/ml TGF-β1 for 6 hours. After that period of time,
chondrocytes were transfected with 50 nM miR-33a in-
hibitor (anti-miR-33a) for 24 hours. Our results
showed that SREBP-2 expression levels were reduced
in chondrocytes treated with 10 ng/ml TGF-β1 to-
gether with 50 nM anti-miR-33a compared with TGF-
β1 treatment (P < 0.001) (Figure 2A).PI3K/Akt pathway is directly associated with TGF-β
receptor
To show whether the PI3K/Akt pathway is directly or
indirectly associated with the TGF-β receptor, we treated
normal chondrocytes with 10 ng/ml TGF-β1 over differ-
ent periods of time (from 0.5 to 24 hours) and found a
rapid induction of Akt phosphorylation, suggesting dir-
ect involvement of PI3K in TGF-β-receptor induced
intracellular signaling (Figure 2B,C).
Regulation of TGF-β1-induced Akt phosphorylation
by miR-33a
Because miR-33a expression was significantly increased
by TGF-β1 stimulation in human chondrocytes and its
inhibition reduced SREBP-2 expression levels, we were
prompted to investigate miR-33a’s role in the PI3K/Akt
pathway. Transfection of normal chondrocytes with 10
ng/ml TGF-β1 plus 30 nM miR-33a for 24 hours re-
sulted in significant increased Akt phosphorylation com-
pared with TGF-β1 treatment alone (Figure 2D,E).
Inhibition of miR-33a in human chondrocytes inhibited
TGF-β1-induced Akt phosphorylation. Total Akt expres-
sion was not changed by transfection of miR-33a or
miR-33a inhibitor (Figure 2F,G).
miR-33a modulates TGF-β1 induced PI3K/Akt signaling
pathway by targeting Smad7
Taking into consideration the fact that the degree of ac-
tivation of the TGF-β signaling pathways is subject to
regulation by a large number of intracellular and extra-
cellular agonists and antagonists, including Smad7 and
Smurf, we performed computational analysis of the 3′
UTR of Smad7 mRNA, a negative regulator of TGF-β
signaling. The TargetScan 6.2 and miRanda prediction
tools showed that Smad7 is a target gene of miR-33a
(Figure 3A).
To verify this prediction, we transfected normal chon-
drocytes with 30 nM miR-33a mimic for 24 hours.
Treatment of normal chondrocytes with miR-33a mimic
resulted in significant upregulation of miR-33a expres-
sion levels compared with negative control (P < 0.05)
(Figure 3B). We observed a significant reduction in
Smad7 mRNA expression compared with untreated cells
(P < 0.05) (Figure 3C). Treatment of OA chondrocytes
with 50 nM miR-33a inhibitor resulted in significant
suppression of miR-33a (Figure 3D) (P < 0.05) and in sig-
nificantly increased Smad7 mRNA expression levels
compared with negative control (P < 0.05) (Figure 3E).
Computational prediction of miR-33a lipid-related
target genes
To investigate the role of miR-33a in regulating lipid-
related genes, we used bioinformatics prediction tools,
which identified three conserved sequences in the 3′-
Figure 1 MicroRNA-33a is elevated in osteoarthritic chondrocytes and is induced by transforming growth factor-β1. (A) Relative
expression of microRNA (miR)-33a in normal and osteoarthritic (OA) chondrocytes (n = 9 for normal chondrocytes from 9 different donors, n = 14
for OA chondrocytes from 14 different donors). U6 was used for normalization of the real-time PCR data. The data are expressed as mean and standard
error of the mean (SEM) of three independent experiments, each of which was run in duplicate. *P < 0.05 as measured using an unpaired Student’s
t-test. (B) Relative expression of sterol regulatory element-binding protein 2 (SREBP-2) in normal and OA chondrocytes (n = 5 for normal chondrocytes
from 5 different donors, n = 10 for OA chondrocytes from 10 different donors). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for
normalization of the real-time PCR data. The data are expressed as mean and SEM of three independent experiments, each of which was run in
duplicate. *P < 0.05 as measured using an unpaired Student’s t-test. (C) and (D) miR-33a expression levels in cultured normal chondrocytes (n = 4 from
4 different donors) following treatment with 10 ng/ml transforming growth factor (TGF)-β1 for 6 hours, 24 hours (C) and 48 hours (D). U6 was used for
normalization of the real-time PCR data. The data are expressed as mean and SEM of two independent experiments, each of which was run in triplicate.
*P < 0.05 compared with control. (E) and (F) SREBP-2 expression levels in cultured normal chondrocytes (n = 5 from 5 different donors) following
treatment with 10 ng/ml TGF-β1 for 6 hours, 24 hours (E) and 48 hours (F). GAPDH was used for normalization of the real-time PCR data. The data are
expressed as mean and SEM of two independent experiments, each of which was run in triplicate. *P < 0.05 compared with control.
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Figure 2 Effect of microRNA-33a on transforming growth factor-β1-mediated phosphoinositide 3-kinase/Akt signaling pathway in
human chondrocytes. (A) Sterol regulatory element-binding protein 2 (SREBP-2) mRNA expression in human normal chondrocytes (n = 3 from 3
different donors) after treatment with 10 ng/ml transforming growth factor (TGF)-β1 with or without microRNA (miR)-33a inhibitor. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used for normalization of the real-time PCR data. The data are expressed as mean and SEM from triplicates
of one representative of three experiments. *P < 0.05 versus negative control, **P < 0.01, #TGF-β1 with miR-33a inhibitor versus TGF-β1. (B) Western blot
showing phosphorylated (p-Akt) and total Akt protein expression levels in normal chondrocytes treated with 10 ng/ml TGF-β1 for 0.5, 2 and 24 hours.
(C) Diagram showing p-Akt protein expression normalized to total Akt using ImageJ software. The result shown represents the mean from three
different blots. *P < 0.05 compared with control. (D) Western blot showing p-Akt and total Akt protein expression levels in normal chondrocytes treated
with TGF-β1, TGF-β1 plus miR-33a or negative control. (E) Diagram showing p-Akt protein expression normalized to total Akt using ImageJ software.
The result shown represents the mean from three different blots. *P < 0.05 compared with control. #TGF-β1 with miR-33a versus TGF-β1. (F) Western
blot showing p-Akt and total Akt protein expression levels in osteoarthritis chondrocytes treated with TGF-β1 and miRNA inhibitor (anti-miR-33a),
followed by treatment of TGF-β1 or negative control. (G) Diagram showing p-Akt protein expression normalized to total Akt using ImageJ software.
The result shown represents the mean from three different blots. *P < 0.05 compared with control. #TGF-β1 with miR-33a inhibitor versus TGF-β1.
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Figure 3 ΜicroRNA-33a affects Smad7 expression in human chondrocytes. (A) TargetScan 6.2 and miRanda identified one conserved
sequence in the 3′ untranslated region of human Smad7 mRNA that was completely complementary to microRNA (miR)-33a. (B) Relative
expression levels of miR-33a in normal human chondrocytes (n = 3 from 3 different donors) transfected with miR-33a mimic or negative control.
U6 was used for normalization of the real-time PCR data. The data are expressed as mean and standard error of the mean (SEM) of three
independent experiments, each of which was run in duplicate. *P < 0.05 versus negative control. (C) Relative expression levels of Smad7 mRNA
24 hours after transfection of 30 nM miR-33a or negative control in normal human chondrocytes (n = 6 from 6 different donors). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used for normalization of the real-time PCR data. The data are expressed as mean and SEM of three
independent experiments, each of which was run in triplicate. *P < 0.05 versus negative control. (D) Relative expression levels of miR-33a in
human osteoarthritis (OA) chondrocytes transfected with miR-33a inhibitor or negative control (n = 3 from 3 different donors). U6 was used for
normalization of the real-time PCR data. The data are expressed as mean and SEM of three independent experiments, each of which was run in
duplicate. *P < 0.05 versus negative control. (E) Relative expression levels of Smad7 mRNA 24 hours after transfection of 50 nM anti-miR-33a or
negative control in human OA chondrocytes (n = 4 from 4 different donors). GAPDH was used for normalization of the real-time PCR data. The
data are expressed as mean and SEM of three independent experiments, each of which was run in triplicate. *P < 0.05 versus negative control.
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complementary to miR-33a (Figure 4A). None of the
other genes examined (ApoA1, SREBP2, LXRα, LXRβ)
had a fully or partially complementary sequence to miR-
33a (data not shown).
miR-33a targets to ATP-binding cassette transporter A1
and suppresses its expression in human chondrocytes
To examine the role of miR-33a in the expression of
genes regulating reverse cholesterol transport (ABCA1,ApoA1, LXRα and LXRβ), normal chondrocytes were
transfected with 30 nM miR-33a mimic for 6 , 24 and
48 hours. miR-33a treatment significantly suppressed
ABCA1 mRNA expression levels at 6, 24 and 48 hours
(P < 0.05) (Figure 4B), as well as ApoA1 mRNA expres-
sion levels at 24 and 48 hours (P < 0.05) (Figure 4C),
which was accompanied by elevated levels of MMP-13
(P < 0.05) (Figure 4D). Transfection of miR-33a mimic
had no effect on the expression levels of LXRα and
LXRβ in human chondrocytes (P > 0.05) (Figure 4E,F).
Figure 4 (See legend on next page.)
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Figure 4 ΜicroRNA-33a affects ATP-binding cassette transporter A1 and apolipoprotein A1 expression in human chondrocytes.
(A) TargetScan 6.2, miRanda and miRDB identified three conserved sequences in the 3′ untranslated region of human ATP-binding cassette
transporter A1 (ABCA1) mRNA that were completely complementary to microRNA (miR)-33a. (B) and (C) Relative expression levels of ABCA1
(B) and apolipoprotein A1 (ApoA1) (C) mRNA at 6, 24 and 48 hours after transfection of 30 nM miR-33a or negative control in normal human
chondrocytes (n = 6 from 6 different donors). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization of the real-time
PCR data. The data are expressed as mean and standard error of the mean (SEM) of two independent experiments, each of which was run in
triplicate. *P < 0.05 versus negative control. (D) Relative expression levels of matrix metalloproteinase (MMP)-13 mRNA at 6, 24 and 48 hours after
transfection of 30 nM miR-33a or negative control in normal human chondrocytes (n = 4 from 4 different donors). GAPDH was used for
normalization of the real-time PCR data. The data are expressed as mean and SEM of two independent experiments, each of which was run in
triplicate. *P < 0.05 versus negative control. (E) and (F) Relative expression levels of liver X receptor α (LXRα) (E) and LXRβ (F) mRNA at 6, 24 and
48 hours after transfection of 30 nM miR-33a or negative control in normal human chondrocytes (n = 4 from 4 different donors). GAPDH was used
for normalization of the real-time PCR data. The data are expressed as mean and SEM of two independent experiments, each of which was run in
triplicate. NS, Not significant.
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To confirm that miR-33a regulates cholesterol efflux-
related genes in a manner that can be reversed by its
inhibitor, OA chondrocytes were treated with 50 nM anti-
miR-33a for 24 and 48 hours, and expression levels of
ABCA1, ApoA1 and MMP-13 were evaluated. Treatment
of OA chondrocytes with anti-miR-33a resulted in signifi-
cantly upregulated ABCA1 and ApoA1 mRNA expression
levels (P < 0.05) (Figure 5A,B), whereas MMP-13 mRNA
expression levels were reduced (P < 0.05) (Figure 5C).
Discussion
A growing body of evidence suggests that the relation-
ship between MetS and OA is not one of cause and ef-
fect, but rather is indicative of an underlying common
set of factors, highlighting OA as a metabolic disorder
[3-6,10,37-39]. miRNAs have key roles in modulating
and maintaining normal physiological conditions, with
their signaling emerging as of great interest as a poten-
tial tool for diagnosis of and therapy for the progression
of a number of diseases, such as OA.
miR-33a plays a crucial role in controlling cholesterol
homeostasis in metabolism-related disorders [26], but so
far no association with OA has been found. It is embed-
ded within intron 16 of SREBP2, a lipid metabolism-
related gene, which has been identified by our group to
be involved in OA pathogenesis [11].
In the present study, we investigated the role of miR-
33a in cholesterol synthesis and cholesterol efflux-
related genes. We found that miR-33a expression levels
were significantly elevated in osteoarthritic chondrocytes
compared with normal chondrocytes, in accordance to
SREBP-2 upregulation. In line with previous findings in
human and mouse tissues, such as HEK293 cells, Hep3B
human hepatoma cells and mouse peritoneal macrophages
[23,29,30,40], our results also suggest that miR-33a is
coexpressed with its host gene in human chondrocytes.
As we previously reported that SREBP-2 can be in-
duced by TGF-β1 in chondrocytes, we proceeded toinvestigate whether TGF-β1 activates miR-33a as well.
We found that miR-33a expression was increased in a
time-dependent manner after TGF-β1 activation, sug-
gesting that the expression levels of miR-33a and
SREBP-2 are coregulated by TGF-β1 at the transcriptional
level. This finding is in accordance with recent studies
which showed that the expression of both miR-33a and
SREBP-2 was increased in a dose- and time-dependent
way after TGF-β1 stimulation in immortalized human
hepatic stellate cells. We also showed that normal
chondrocytes stimulated with TGF-β1, followed by
transient transfection of anti-miR-33a, exhibited re-
duced expression levels of SREBP-2, supporting the
strong association between SREBP-2 and its intronic
miRNA, miR-33a [23,29,30].
Furthermore, we have also previously shown that the
induction of SREBP-2 by TGF-β1 in human chondro-
cytes is mediated through the PI3K/Akt pathway [11].
To show whether the PI3K/Akt pathway is directly or
indirectly associated with the TGF-β receptor, we treated
normal chondrocytes with TGF-β1 and found rapid in-
duction of Akt phosphorylation, supporting the direct
involvement of PI3K in TGF-β receptor-induced intra-
cellular signaling [41,42]. This pathway is important in
regulating the production of MMPs by chondrocytes
[43]. It has also been suggested to be implicated in dif-
ferent pathological conditions, cancer, diabetes, viral in-
fections [44] and, more recently, hepatic fibrosis, and
thus it is an important player in the regulation of lipid
metabolism [45]. We found that transient transfection of
human chondrocytes with miR-33a plus TGF-β1 and en-
hanced Akt phosphorylation, whereas inhibition of miR-
33a resulted in subsequent inhibition of TGF-β1-induced
Akt phosphorylation. Our previous result is in accordance
with the study by Li et al., who reported that inhibition of
miR-33a in LX-2 cells inhibited the phosphorylation of
Akt after TGF-β1 treatment [45]. The above findings sug-
gest the involvement of miR-33a in the regulation of the
TGF-β1/PI3K/Akt/SREBP-2 signaling pathway responsible
for increased cholesterol synthesis in OA.
Figure 5 Anti-microRNA-33a affects ATP-binding cassette transporter A1 and apolipoprotein A1 expression in human chondrocytes.
(A) Relative expression levels of ATP-binding cassette transporter A1 (ABCA1) mRNA 24 and 48 hours after transfection of 50 nM anti-microRNA
(miR)-33a or negative control in human osteoarthritis (OA) chondrocytes (n = 5 from 5 different donors). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used for normalization of the real-time PCR data. The data are expressed as mean and standard error of the mean (SEM) of two independent
experiments, each of which was run in triplicate. *P< 0.05 versus negative control. (B) Relative expression levels of apolipoprotein A1 (ApoA1) mRNA 24
and 48 hours after transfection of 50 nM anti-miR-33a or negative control in human OA chondrocytes (n = 5 from 5 different donors). GAPDH was used for
normalization of the real-time PCR data. The data are expressed as mean and SEM of two independent experiments, each of which was run in triplicate.
*P< 0.05 versus negative control. (C) Relative expression levels of matrix metalloproteinase (MMP)-13 mRNA 24 and 48 hours after transfection of 50 nM
anti-miR-33a or negative control in human OA chondrocytes (n = 5 from 5 different donors). GAPDH was used for normalization of the real-time PCR data.
The data are expressed as mean and SEM of two independent experiments, each of which was run in triplicate. *P< 0.05 versus negative control.
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a large number of intracellular and extracellular activa-
tors and inhibitors regulate the degree of activation of the
TGF-β signaling pathways. Among them, Smad7, an in-
hibitory Smad, is a key regulator of TGF-β signaling
[42,46-48]. In the present study, we showed that miR-33a
targets Smad7 in human chondrocytes, suggesting that
miR-33a possibly regulates TGF-β1/PI3K/Akt signaling
through modulating Smad7 expression. Interestingly,
Huang et al. [49] recently demonstrated that Smad7 is tar-
geted by miR-33a in LX-2 cells, thus highlighting its inhib-
ition as a possible mechanism responsible for miR-33aprofibrogenic effects in hepatic stellate cells. In an attempt
to investigate the role of miR-33a in the regulation of re-
verse cholesterol transport, we investigated its effect in the
cholesterol efflux-related genes ABCA1, ApoA1, LXRα and
LXRβ. Taking into consideration the facts that ABCA1
and ApoA1 expression levels were previously shown by
our group to be significantly reduced in OA chondrocytes
compared with normal chondrocytes [10] and that ABCA1
is a direct and specific target of miR-33a, as evidenced by
previous studies [23-25,28] and by our bioinformatics ana-
lysis, we investigated the effect of this miRNA on genes
regulating cholesterol efflux in chondrocytes. We found
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sulted in significant reduction of ABCA1 and ApoA1
mRNA expression levels, accompanied by increased levels
of MMP-13. As evidenced by bioinformatics analysis,
miR-33a is fully complementary to the 3′-UTR of ABCA1,
directly resulting in degradation of ABCA1’s mRNA tran-
scripts. As ApoA1 is not a target gene of miR-33a, the re-
duced expression we observed after miR-33a treatment in
normal chondrocytes could be considered an indirect ef-
fect caused by the inhibition of ABCA1. Interestingly, miR-
33a had no effect on LXRα and LXRβ expression levels, as
we showed by bioinformatics analysis that there are no
binding sites on the LXRα and LXRβ gene regions for this
miRNA. On the basis of our results, miR-33a emerges as
part of a different regulatory mechanism of genes involved
in cholesterol efflux, apart from the traditional ligand-
activated transcription factor LXR, providing novel evi-
dence of the contribution of miR-33a to the blockage of
reverse cholesterol transport in human chondrocytes.
To confirm that miR-33a regulates cholesterol efflux
genes in a way that can be reversed by its inhibitor, we
treated OA chondrocytes with anti-miR-33a. Introduc-
tion of antisense oligonucleotides directed against miR-
33a indeed resulted in strongly increased ABCA1 and
ApoA1 expression levels, and it also caused reduced ex-
pression of MMP-13, the most abundantly expressed cata-
bolic gene in OA. The above findings are consistent with
the reported regulation of ABCA1 by miR-33a in cell lines
such as human HepG2 liver carcinoma cells, IMR-90 nor-
mal human fibroblasts and the mouse macrophage cell line
J774 [24]. Moreover, in studies in animal models of hyper-
cholesterolemia and atherosclerosis, researchers have re-
ported that miR-33a suppresses the expression of ABCA1
and lowers HDL levels, whereas inhibition of miR-33 in-
creases ABCA1 and HDL levels [25,30,31].
Conclusions
We provide novel evidence for the implication of miR-
33a, a SREBP-2 intronic miRNA, in OA pathogenesis,
identifying it as a dual regulator of cholesterol synthesis
and cholesterol efflux-related genes in OA chondrocytes,
suggesting its potential use as a novel target for the
amelioration of the OA phenotype.
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